Rapala VMC Corporation, Stock Exchange Release, November 24, 2025 at 08:30 p.m. EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Rapala VMC Corporation (“Rapala VMC”) announces today the final results of the invitation to the holders of its hybrid capital securities ( ...

LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced the final results of its cash tender offer (the “Tender Offer”) to repurchase up to 10,950,165 shares of its common stock, at a fixed purchase price of $17.75 per share, for an aggregate purchase price of up to approximately $194.4 million. The Tender Offer expired at 5:00 p.m. Eastern Time on November 18, 2025. The expiration of the Tender Offer concludes the Company’s pre ...

Accessibility StatementSkip Navigation WILMINGTON, Del., Nov. 18, 2025 /PRNewswire/ --Â DuPont (NYSE: DD) announced today the early results of its previously announced tender offer (the "Tender Offer") to purchase for cash up to $739,256,000 aggregate principal amount (the "Maximum Tender Amount") of its 5.419% Notes due 2048 issued on November 28, 2018 (the "2048 Notes"). The Tender Offer is being made pursuant to the terms and conditions set forth in the Offer to Purchase, dated November 3, 2025 (the "Off ...

Core Points - LAVA Therapeutics announced that approximately 87% of its outstanding common shares were validly tendered in the tender offer by XOMA Royalty Corporation, satisfying the minimum tender condition [1] - The subsequent offering period for LAVA shareholders to tender their shares will expire on November 20, 2025, and shares tendered during this period cannot be withdrawn [2] - LAVA intends to voluntarily delist its common shares from Nasdaq, contingent upon the completion of the acquisition by XOMA Royalty [3] Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships with Johnson & Johnson and Pfizer for specific cancer treatments [4]

Group 1 - The Total Return Securities Fund has filed a registration statement with the SEC for a rights offering, allowing shareholders to purchase additional shares at 85% of the net asset value (NAV) per share on the expiration date of December 5, 2025 [1] - Shareholders of record on November 14, 2025, will receive one non-transferable right for each share held, and those who fully exercise their rights may subscribe for additional shares not taken by other rights holders [1] - The Board plans to authorize a tender offer to buy back between 15% and 30% of the Fund's outstanding shares at a price of at least 98% of NAV, depending on the results of the rights offering [2] Group 2 - A registration statement on Form N-2 related to the securities has been filed with the SEC but is not yet effective, meaning the securities cannot be sold or offered until it becomes effective [3] - This press release serves informational purposes only and does not constitute an offer to purchase or solicit an offer to sell shares of the Fund's common stock [4] - If a tender offer is initiated, the Fund will file a Tender Offer Statement with the SEC, which will include important information regarding the terms and conditions of the tender offer [4]

Core Points - Cogna Educação S.A. has extended the expiration date of its cash tender offer for Vasta Platform Limited's Class A common shares to December 10, 2025 [1][2] - The extension is due to the need for additional time for the SEC to review the Tender Offer Documents, which has been impacted by the U.S. government shutdown [2] - As of the previous expiration date, approximately 96.3% of the outstanding shares had been validly tendered into the offer [3] Offer Details - The tender offer was initially announced on September 17, 2025, and has undergone amendments on September 24, 2025, and October 16, 2025 [1][4] - The offer price is set at U.S.$5.00 per Class A common share [1] - The offer is subject to the conditions outlined in the Offer to Purchase, which includes the satisfaction or waiver of all conditions [4] Agents Involved - D.F. King & Co., Inc. serves as the information agent for the offer [5] - Equiniti Trust Company, LLC is the tender agent for the offer [5] - Itau BBA USA Securities, Inc. acts as the dealer manager for the offer [5]

Core Viewpoint - Thomas J. Herzfeld Advisors, Inc. and Herzfeld Credit Income Fund, Inc. announced the final results of a cash tender offer to purchase up to 5% of its outstanding common shares at 97.5% of the Fund's net asset value as of October 15, 2025 [1][3]. Summary by Relevant Sections Tender Offer Details - The Fund offered to purchase up to 5% or 845,433 shares of its outstanding common shares [2]. - A total of 11,603,885 shares were properly tendered, with 845,433 shares to be purchased [2]. - The pro-ration factor for the tender offer was calculated at 7.2858%, meaning that only a portion of the shares tendered would be accepted [2][4]. - The purchase price for the shares accepted was set at $2.5935, which is equal to 97.5% of the Fund's NAV per share [2][3]. Company Background - Thomas J. Herzfeld Advisors, Inc. is an SEC-registered investment advisor established in 1984, specializing in investment analysis and account management in closed-end funds [6].

Core Points - Thomas J. Herzfeld Advisors, Inc. and Herzfeld Credit Income Fund, Inc. announced preliminary results of a cash tender offer to purchase up to 5% of its outstanding common shares at 97.5% of the Fund's net asset value as of October 15, 2025 [1][2] Group 1: Tender Offer Details - The tender offer amount was up to 5% or 845,433 shares, with 11,603,885 shares properly tendered [2] - The purchase price for properly tendered shares was set at $2.5935, which is equal to 97.5% of the Fund's NAV per share as of the close of trading on October 15, 2025 [2] - If the number of common shares tendered exceeds the amount offered, the Fund will purchase shares on a pro-rata basis [3] Group 2: Final Results Announcement - The results are based on preliminary information and are subject to adjustment, with final results expected to be announced around October 20, 2025 [4] Group 3: Company Background - Thomas J. Herzfeld Advisors, Inc. is an SEC-registered investment advisor founded in 1984, specializing in investment analysis and account management in closed-end funds [5]

Core Points - LXP Industrial Trust announced a tender offer to purchase up to $150,000,000 of its 6.750% Notes due 2028, excluding accrued interest and related fees [1][4][8] - The total consideration for the Notes validly tendered before the Early Tender Deadline is calculated based on a fixed spread and includes an early tender premium of $30.00 per $1,000 [3][5] - The Offer will expire on October 30, 2025, unless extended or terminated earlier by the Company [4] Offer Details - The principal amount of the Notes outstanding is $300,000,000, with a Tender Cap of $150,000,000 [2] - The reference U.S. Treasury Security yield is 3.375%, with a fixed spread of 50 basis points [2] - Due to the Tender Cap being exceeded, the Company will accept approximately $140,000,000 of the Notes validly tendered, applying a proration rate of about 75.3% [8] Tender Process - Holders of Notes who tendered before the Early Tender Deadline will receive accrued interest along with the Total Consideration [6] - Withdrawal rights for the Notes expired on October 15, 2025, at 5:00 p.m. New York City time [7][9] - The settlement for the accepted Notes is expected to occur on October 20, 2025, subject to conditions being met [8]

Core Points - Fannie Mae announced the results of its fixed-price cash tender offers for certain Connecticut Avenue Securities (CAS) Notes [1] - A total of $2,000 million in original principal amount of Notes were validly tendered by the expiration time of October 3, 2025 [2] Summary by Category Tender Offer Details - The Offers were conducted for specific CAS Notes as outlined in the Offer Documents dated September 29, 2025 [1] - The settlement date for the accepted Notes is expected to be October 7, 2025, with additional purchases for those using the Notice of Guaranteed Delivery on October 8, 2025 [6] Tendered Notes Information - The total original principal amount tendered includes $27,281,728 of Notes tendered using the Notice of Guaranteed Delivery [5] - The aggregate original principal amount of Notes tendered was $2,250,877,000, representing 88.87% of the total [4] Specific Notes Performance - Connecticut Avenue Securities, Series 2017-C03, Class 1B-1 Notes had a 100% tender rate with an original principal balance of $26,045,000 [3] - Connecticut Avenue Securities, Series 2017-C06, Class 2B-1 Notes had a tender rate of 1.01%, with $195,000 tendered from an original balance of $19,316,000 [3] - Connecticut Avenue Securities, Series 2021-R02, Class 2M-2 Notes had a tender rate of 81.03%, with $351,667,668 tendered from an original balance of $434,007,000 [4]